632 related articles for article (PubMed ID: 17966888)
1. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
Sliwowska I; Kopczyński Z
Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
[TBL] [Abstract][Full Text] [Related]
2. Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer.
Daniele A; Zito AF; Giannelli G; Divella R; Asselti M; Mazzocca A; Paradiso A; Quaranta M
Anticancer Res; 2010 Sep; 30(9):3521-7. PubMed ID: 20944132
[TBL] [Abstract][Full Text] [Related]
3. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer.
Quaranta M; Daniele A; Coviello M; Venneri MT; Abbate I; Caringella ME; Di Tardo S; Divella R; Trerotoli P; Di Gennaro M; Schittulli F; Fransvea E; Giannelli G
Anticancer Res; 2007; 27(5B):3593-600. PubMed ID: 17972522
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer.
Shah FD; Shukla SN; Shah PM; Shukla HK; Patel PS
Indian J Cancer; 2009; 46(3):194-202. PubMed ID: 19574670
[TBL] [Abstract][Full Text] [Related]
5. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
6. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.
Scorilas A; Karameris A; Arnogiannaki N; Ardavanis A; Bassilopoulos P; Trangas T; Talieri M
Br J Cancer; 2001 Jun; 84(11):1488-96. PubMed ID: 11384099
[TBL] [Abstract][Full Text] [Related]
8. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.
Zhang L; Shi J; Feng J; Klocker H; Lee C; Zhang J
Prostate Cancer Prostatic Dis; 2004; 7(4):327-32. PubMed ID: 15356679
[TBL] [Abstract][Full Text] [Related]
9. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer].
Demeter A; Szirmai K; Oláh J; Papp Z; Jeney A
Orv Hetil; 2004 Aug; 145(31):1617-24. PubMed ID: 15384859
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the clinical significance of gelatinase activity in patients with juvenile idiopathic arthritis using quantitative protein substrate zymography.
Peake NJ; Foster HE; Khawaja K; Cawston TE; Rowan AD
Ann Rheum Dis; 2006 Apr; 65(4):501-7. PubMed ID: 16150790
[TBL] [Abstract][Full Text] [Related]
11. Low serum level of pro-matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma.
Kuvaja P; Talvensaari-Mattila A; Pääkkö P; Turpeenniemi-Hujanen T
Hum Pathol; 2006 Oct; 37(10):1316-23. PubMed ID: 16949931
[TBL] [Abstract][Full Text] [Related]
12. Serum MMP-9 level associated with initiation and progression steps of breast cancer in the Iranian population.
Motovali-Bashi M; Sadeghi M; Hemmati S
Reprod Sci; 2010 Jun; 17(6):585-9. PubMed ID: 20338991
[TBL] [Abstract][Full Text] [Related]
13. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.
Wu CY; Wu MS; Chiang EP; Chen YJ; Chen CJ; Chi NH; Shih YT; Chen GH; Lin JT
Clin Cancer Res; 2007 Apr; 13(7):2054-60. PubMed ID: 17404086
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase-2 and matrix metalloproteinase-9 type IV collagenases in serum of patients with pleural effusions.
Di Carlo A; Terracciano D; Mariano A; Macchia V
Int J Oncol; 2005 May; 26(5):1363-8. PubMed ID: 15809729
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein has modest prognostic value in locally advanced breast carcinoma patients treated with an adjuvant antiestrogen therapy.
Rahko E; Jukkola A; Melkko J; Paavo P; Bloigu R; Talvensaari-Mattila A; Turpeenniemi-Hujanen T
Anticancer Res; 2004; 24(6):4247-53. PubMed ID: 15736480
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer.
Papathoma AS; Petraki C; Grigorakis A; Papakonstantinou H; Karavana V; Stefanakis S; Sotsiou F; Pintzas A
Anticancer Res; 2000; 20(3B):2009-13. PubMed ID: 10928143
[TBL] [Abstract][Full Text] [Related]
17. Measuring gelatinase activity in colorectal cancer.
Baker EA; Leaper DJ
Eur J Surg Oncol; 2002 Feb; 28(1):24-9. PubMed ID: 11869009
[TBL] [Abstract][Full Text] [Related]
18. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
[TBL] [Abstract][Full Text] [Related]
19. Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression.
Patel S; Sumitra G; Koner BC; Saxena A
Clin Biochem; 2011 Jul; 44(10-11):869-72. PubMed ID: 21565179
[TBL] [Abstract][Full Text] [Related]
20. Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma.
Patel BP; Shah PM; Rawal UM; Desai AA; Shah SV; Rawal RM; Patel PS
J Surg Oncol; 2005 May; 90(2):81-8. PubMed ID: 15844188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
